



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

Date: 30th May, 2022

To,
The DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2022 UNDER REGULATION 33 OF THE SECURITIES & EXCHANGE BOARD OF INDIA (LISTING OBLIGATION & DISCLOSURE REQUIREMENTS) REGULATION, 2015

Sir/ Madam,

This is with reference to the above; Please find attached the Audited Financial Results for the year ended 31st March, 2022 as per format prescribed under the regulation 33 of the Securities & Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulation, 2015. Please take the attached Financials on your record.

Kindly take on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited


Sudhir Sethi
Chairman & Director
DIN: 00090172





BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com
CIN : L02423MP1993PLC007840

ANNEXURE I

Submission of Audited Financial Result by Companies Other than Banks


Part I		Statement of standalone Audited Result for the Quarter/ year ended 31/03/2022				
		Quarter ended			Year Ended	
Particulars	3 months ended (31-03-2022)	Preceding 3 months ended (31-12-2021)	Corresponding 3 months ended in the previous year (31-03-2021)	Year to date figures for current period ended (31-03-2022)	Year to date figures for previous period ended (31-03-2021)	
	Audited	Unaudited	Audited	Audited	Audited	
1 Revenue From Operations						
Net sales or Revenue from Operations	34691	31806	60647	146037	140929	
Other operating revenues	513	383	-3902	1649	1871	
Total Revenue from operations (net)	35204	32189	56745	147686	142800	
2 Expenses						
(a) Cost of materials consumed	27882	17105	24691	87072	74517	
(b) Purchases of stock-in-trade	0	0	0	0	0	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-3970	81	10750	-3041	-327	
(d) Employee benefit expense	2883	3914	3278	13109	11768	
(e) Finance costs	993	1154	1412	4368	4657	
(f) Depreciation and amortisation expense	2712	2718	2359	10865	12735	
(g) Other Expenses	11286	8639	15617	44816	40489	
Total expenses	41786	33611	58107	157189	143839	
3 Profit (loss) from operations before exceptional items and tax	-6582	-1422	-1362	-9503	-1039	
4 Exceptional items	0	0	4518	0	4518	
5 Profit (loss) before tax	-6582	-1422	3156	-9503	3479	
6 Tax Expense						
Current tax	91	-403	-460	91	8	
Deferred tax	-1929	0	2444	-3004	1075	
Total Tax Expenses	-1838	-403	1984	-2913	1083	
7 Net Profit (loss) for the period from continuing operations	-4744	-1019	1172	-6590	2396	
8 Net Profit (loss) from discontinuing operations before tax	0	0	0	0	0	
9 Tax Expense of discontinuing operations	0	0	0	0	0	
10 Net Profit (loss) from discontinuing operations after tax	0	0	0	0	0	
11 Net Profit (loss) for the Period	-4744	-1019	1172	-6590	2396	
12 Other comprehensive income						
(i) Items that will not be reclassified to Statement of Profit and Loss	237	-36	570	232	643	
(ii) Items that will be reclassified to Statement of Profit and Loss	0	0	0	0	0	
13 Total Comprehensive Income	-4507	-1055	1742	-6358	3039	
14 Details of equity share capital						
Paid-up equity share capital	50717.000	50717.000	50717.000	50717.000	50717.000	
Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	
15 Earnings per share						
i Basic earnings per share before extraordinary items	-0.94	-0.20	0.23	-1.30	0.47	
ii Diluted earnings per share before extraordinary items	-0.94	-0.20	0.23	-1.30	0.47	

Notes to the Results:

- The above Financial Results for the quarter and year ended 31st March 2022 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Saturday 30th May 2022 and the financial result have been audited by the Statutory Auditors of the Company. The statutory Auditors have expressed an unmodified audit opinion on the results.
- This Statement is as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (The Act) read with relevant Rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).
- The figures for the quarter ended March 31, 2022 and the quarter ended March 31, 2021 are the balancing figures between the audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditors of the Company.
- Figures for the previous periods have been regrouped, wherever necessary and minus figures are shown in brackets.
- Depreciation on fixed assets is provided on written down value method as per the estimated remaining useful life of assets.
- Revenue from Operations is net of GST.
- Earnings per share amount is shown in Rupees.
- The Company has identified "Pharmaceutical Industry" as the single operating segment for the continued operations in the standalone financial statements as per Ind AS 108 "Operating Segments".

For and on behalf of the Board of Directors of
BERYL DRUGS LIMITED

Sanjay Sethi
Managing Director
DIN 00090277



Date: 30th May 2022
Place: Indore

BERYL DRUGS LIMITED

133, KANCHAN BAGH
INDORE(M.P.)


STATEMENT OF ASSETS AND LIABILITIES AS AT 31st March 2022

CIN: L02423MP1993PLC007840

(Rs. in 000)

PARTICULARS	As at 31st March 2022	As at 31st March 2021
ASSETS		
Non-current assets		
Property plant and equipment	58,595	73,244
Capital Work-in-Progress	-	-
Investment Property	1,800	1,960
Other Intangible assets	22	39
Financial Assets		
Investments	1,585	1,196
Trade Receivables	-	-
Loans	-	-
Other Financial Assets	1,350	815
Deferred Tax Assets (Net)	897	-
Other Non-current assets	7,701	7,706
Total Non-Current assets	71,950	84,960
Current Assets		
Inventories	29,782	22,690
Financial Assets		
Investments	-	-
Trade receivables	44,485	45,408
Cash and cash equivalents	2,714	4,521
Loans	-	-
Other Financial Assets	9,463	7,490
Current Tax Asset (Net)	1,303	1,088
Other Current Assets	18,075	19,860
Assets held for sale	466	466
Total Current assets	1,06,289	1,01,522
Total Assets	1,78,238	1,86,482
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	50,937	50,937
Other Equity	21,999	28,357
Total Equity	72,936	79,294
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	16,752	19,863
Provisions	3,626	3,140
Deferred Tax Liabilities (Net)	-	2,053
Other Non-Current Liabilities	-	-
Total non-current liabilities	20,378	25,056
Current liabilities		
Financial Liabilities		
Borrowings	36,184	31,374
Trade payables	-	-
Outstanding dues of Micro, Small and Medium Enterprises	4,940	1,264
Outstanding dues of creditors other than MSME	16,794	20,938
Other Financial Liabilities	9,803	11,916
Other Current liabilities	4,173	3,986
Provisions	1,031	655
Liabilities Classified as held for Sale	12,000	12,000
Total current liabilities	84,924	82,132
Total Liabilities	1,05,302	1,07,188
Total Equity and Liabilities	1,78,238	1,86,482

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS




SANJAY SETHI
 (MANAGING DIRECTOR)
 DIN : 00090277


PLACE: INDORE
DATE : 30.05.2022

BERYL DRUGS LIMITED
CIN-L02423MP1993PLC007840
133, KANCHAN BAGH
INDORE (M.P.)
CASH FLOW STATEMENT
FOR THE YEAR ENDED 31st MARCH, 2022

	(Rs.in 000)	
	2021-22	2020-21
A: CASH FLOW FROM OPERATING ACTIVITIES		
Net Loss Before Tax as per Statement of Profit and Loss	(9,503)	3,480
Adjusted for:		
Depreciation / Amortisation Expense	10,865	12,735
Rental Income	(1,273)	(1,262)
Interest Income	(139)	(173)
Finance costs	4,336	4,657
Profit on sale of Investments	0	(4,519)
<i>Operating Profit before Working Capital Changes</i>	<i>4,286</i>	<i>14,918</i>
Adjusted for:		
Inventories	(7,092)	(11,116)
Increase/ (Decrease) in Trade Payables	(468)	4,180
(Increase) / Decrease in Trade Receivables	922	(10,867)
Other Current Assets	1,784	(2,798)
Other Financial Assets	(2,509)	(107)
Other Financial Liabilities	(2,112)	(2,713)
Other Current Liabilities	729	11,584
Changes in Working Capital Limits	1,682	(393)
Provisions	862	911
Cash Generated from Operations	(1,915)	3,600
Taxes Paid (Net)	(952)	(215)
Net Cash flow from Operating Activities	(2,867)	3,385
B: CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible and intangible assets	(4,155)	(10,529)
Proceeds from Government Grant in respect of tangible assets	8,117	8,117
Capital Advances and Others	5	(6,190)
Proceeds from Sale of Investments	0	9,716
Interest Income	139	173
Rental Income	1,273	1,262
Net Cash flow (Used in) Investing Activities	5,379	2,550
C: CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Long Term Borrowings	19,218	7,600
Repayment of Long Term Borrowings	(27,701)	(8,321)
Short Term Borrowings	8,500	0
Finance Costs	(4,336)	(4,657)
Net Cash flow from/(Used in) Financing Activities	(4,319)	(5,377)
Net (Decrease) in Cash and Cash Equivalents	(1,807)	558
Opening Balance of Cash and Cash Equivalents	4,521	3,963
Closing Balance of Cash and Cash Equivalents (As per Note 13)	2,714	4,521

- The above Cash Flow Statement has been prepared under the Indirect method as set out on Ind AS 7 "Statement of Cash Flows"
- Figures for the Previous year have been re-arranged and re-grouped wherever necessary to confirm with the current year classification.
- Figures in the brackets represent Outflows.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS



SANJAY SETHI
(MANAGING DIRECTOR)
DIN:00090277



Independent Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

To,
The Board of Directors
Beryl Drugs Limited
Indore

Opinion

We have audited the quarterly financial results of M/s **Beryl Drugs Limited** ("The Company") for the quarter ended 31st March, 2022 and the year to date results for the period 1st April, 2021 to 31st March, 2022 attached herewith, being submitted by the Company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and the other accounting principles generally accepted in India; of the net loss and other comprehensive income and other financial information for the quarter ended 31st March, 2022 as well as the year to date results for the period from 1st April, 2021 to 31st March, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Financial Results

These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors is responsible for the preparation of these financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



• Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the third quarter of the current financial year ending December 31, 2021 which were subjected to a limited review by us, as required under the Listing Regulations.

For Prateek Jain & Co.
Chartered Accountants
FRN: 0009494C

Prateek Jain

Prateek Jain
(Proprietor)
M.No. 079214



Place:-INDORE
Date: 30/05/2022
UDIN:22079214AJWSAA1603



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

30th May, 2022

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
MUMBAI – 400 001

Subject: Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31st March, 2022.

Scrip Code: 524606

Dear Sirs,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31st March, 2022 as audited by the Auditors of the Company.

DECLARATION

Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25th May, 2016 and further amendment dated 27th May, 2016, We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of M/s Beryl Drugs Limited for the financial year ended on 31.03.2022, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

Sanjay Sethi
Managing Director
DIN: 00090277



For Beryl Drugs Limited

Ashish Baraskar
Chief Financial Officer